Rolipram reverses scopolamine-induced and time-dependent memory deficits in object recognition by different mechanisms of action

https://doi.org/10.1016/j.nlm.2005.09.002Get rights and content

Abstract

In this study, the effect of the selective phosphodiesterase type 4 (PDE4) inhibitor rolipram on memory performance was investigated using the object recognition task. First, three doses of rolipram (0.01, 0.03 or 0.1 mg/kg) were tested with a 24 h delay between the learning (T1) and the test (T2) trial. Doses of rolipram were injected at different time points (30 min before T1, immediately after T1 or 3 h after T1). In a second experiment, the effects of rolipram (0.03, 0.1 or 0.3 mg/kg) were tested in combination with scopolamine (0.1 mg/kg) applying a 1 h delay between trials. Both substances were administered 30 min before T1. Using a 24 h interval, rolipram showed an improvement in long-term memory performance when injected 3 h after T1 at a dose of 0.03 mg/kg. Further, rolipram reversed the scopolamine-induced short-term memory deficit at a dose of 0.1 mg/kg. Although the improved memory performance in both conditions is likely to be explained by elevated cAMP levels, two separate working mechanisms might explain these effects.

Introduction

Cyclic adenosine monophosphate (cAMP) plays an important role in intracellular signaling (Bailey, Bartsch, & Kandel, 1996) and in processes of neuroplasticity such as long-term potentiation (LTP). Hippocampal LTP has been proposed to be a neurophysiological correlate of memory (Bliss & Collingridge, 1993). LTP consists of two phases, an early phase (E-LTP), which does not require gene transcription and lasts less than 3 h and a late phase (L-LTP) depending on gene transcription and protein synthesis and which lasts longer (>3 h). The postsynaptic cAMP/protein kinase A (PKA)/cAMP responsive element binding protein (CREB) pathway, as well as the postsynaptic cGMP/PKG/CREB pathway, are involved in L-LTP (Frey et al., 1993, Impey et al., 1996, Lu and Hawkins, 2002, Lu et al., 1999, Slack and Walsh, 1995).

Rolipram is a selective inhibitor of the phosphodiesterase type 4 (PDE4) enzyme, which hydrolyzes cAMP. Thus, PDE4 inhibition enhances the intracellular availability of cerebral cAMP in the absence of direct stimulation of neurotransmitter receptors (Silvestre, Fernandez, & Palacios, 1999). Studies investigating PDE4 function using rolipram indicate that cAMP is involved in neural processes that underlie learning and memory (Bach et al., 1999, Barad et al., 1998, Zhang and O’Donnell, 2000b). Accordingly, a substantial amount of studies have shown a positive effect of PDE4 inhibition on spatial memory (Bach et al., 1999, Gong et al., 2004, Nagakura et al., 2002), inhibitory avoidance learning (Egawa et al., 1997, Ghelardini et al., 2002, Imanishi et al., 1997, Randt et al., 1982, Zhang et al., 2000a, Zhang and O’Donnell, 2000b), contextual fear conditioning (Barad et al., 1998, Gong et al., 2004) and object recognition memory (Bourtchouladze et al., 2003). Moreover, several studies have shown an involvement of PDE4 inhibitors in working and reference memory (Egawa et al., 1997, Zhang et al., 2000a, Zhang et al., 2004, Zhang and O’Donnell, 2000b).

Previous work showed that intra-hippocampal infusion of 8Br-cAMP improved memory performance when injected 3 or 6 h after one-trial training, but not when injected directly after the training trial (Bernabeu et al., 1997, Bernabeu et al., 1996, Prickaerts et al., 2002a). There is additional evidence that the late phase of memory consolidation is modulated by a cAMP/PKA signaling pathway in the hippocampus (Bernabeu et al., 1997). To our knowledge, all studies that claim to improve memory performance via the cAMP/PKA pathway administered rolipram before the training trial. However, the late phase of memory consolidation, in which the cAMP/PKA pathway is involved, occurs approximately 3 h after training. At this time point cAMP levels are probably minimal due to its metabolic clearance (T1/2 = 1–3 h, Krause & Kuhne, 1988). Therefore, another mechanism of action is probably responsible for the memory enhancing effects of rolipram when injected before T1. However, to our knowledge there is no profound evaluation of the effects of cAMP on early versus late consolidation. Furthermore, most cAMP evaluating studies have investigated the effects of cAMP via rolipram treatment in a scopolamine-induced short-term memory deficit model. Therefore, we decided to test the effects of rolipram on long-term memory performance by administering the drug at different time points.

To study the memory enhancing properties of rolipram, we investigated its effects in an object recognition task (ORT) (Ennaceur & Delacour, 1988). The ORT is a memory test that relies on a rat’s innate explorative behavior. In the first trial, the animal is presented with two objects. In the second trial, after a variable delay, one familiar and one new object are presented. In both trials, the amount of time spent exploring the objects is recorded. If an animal has memory of the objects presented in trial 1 (T1), it will explore the novel object more in the second trial (T2). Depending on the time of treatment, drug effects on acquisition, consolidation or retrieval of object memory can be tested (Prickaerts, Sik, van der Staay, de Vente, & Blokland, 2005). Treatments before the first trial influence acquisition or early consolidation processes, whereas treatments after T1 will affect early or late consolidation processes. The present study investigated the effects of different doses of rolipram on different long-term memory processes, i.e., acquisition (by injecting the drug 30 min before T1), early (by injecting the drug immediately after T1) and late (by injecting the drug 3 h after T1) consolidation, by using a 24 h delay. In addition, rolipram was tested in the scopolamine model for short-term memory deficits using a 1 h delay. This was done to replicate previous findings and for comparison of different dose–response curves, i.e., long-term vs. short-term memory. Of note, the effects of rolipram on the scopolamine deficit model were never before examined in the object recognition task.

Section snippets

Animals

All experimental procedures were approved by the local ethical committee of the Maastricht University for animal experiments according to governmental guidelines. Twelve 5-month-old male Wistar rats (Charles River, The Netherlands) were used (413–464 g). The animals were housed individually in standard type 3 Makrolon cages on sawdust bedding in an air-conditioned room (about 20 °C). They were kept under a reversed 12/12-h light/dark cycle (lights on from 18:00 to 6:00 h) and had free access to

Treatment: 30 min before T1

The results of treatment with rolipram 30 min before the first trial are summarized in Table 2A. No location preference was found in any of the treatment sessions (data not shown). In T1, the total level of exploration was different between treatment conditions (e1: F (3, 43) = 5.17, P < .01). Post hoc comparisons showed that the level of exploration in the highest dose condition (0.1 mg/kg) was lower than in the other treatment conditions (Duncan post hoc). For T2 no difference between treatment

Discussion

In the present study, we found that rolipram reverses the time-dependent decreased memory performance in object recognition when injected 3 h after the acquisition trial. Since, rolipram did not improve memory when injected 30 min before T1 or immediately after T1 it is assumed that PDE4 inhibition improves late-phase consolidation. Corroborating previous studies, rolipram reversed the scopolamine-induced deficit. Notably, the dose of rolipram required to reverse the scopolamine deficit (0.1 

References (33)

  • A. Sik et al.

    Performance of different mouse strains in an object recognition task

    Behavioural Brain Research

    (2003)
  • J.S. Silvestre et al.

    Preliminary evidence for an involvement of the cholinergic system in the sedative effects of rolipram in rats

    Pharmacology, Biochemistry, and Behaviour

    (1999)
  • J.R. Slack et al.

    Effects of a cAMP analogue simulate the distinct components of long-term potentiation in CA1 region of rat hippocampus

    Neuroscience Letters

    (1995)
  • H.T. Zhang et al.

    Inhibition of cyclic AMP phosphodiesterase (PDE4) reverses memory deficits associated with NMDA receptor antagonism

    Neuropsychopharmacology

    (2000)
  • M.E. Bach et al.

    Age-related defects in spatial memory are correlated with defects in the late phase of hippocampal long-term potentiation in vitro and are attenuated by drugs that enhance the cAMP signaling pathway

    Proceedings of the National Academy of Sciences United States of America

    (1999)
  • C.H. Bailey et al.

    Toward a molecular definition of long-term memory storage

    Proceedings of the National Academy of Sciences United States of America

    (1996)
  • Cited by (117)

    • Targeting phosphodiesterase 4 as a therapeutic strategy for cognitive improvement

      2023, Bioorganic Chemistry
      Citation Excerpt :

      In mice treated with Aβ1-40, decreased phosphorylated CREB is reversed by treatment with 3 (rolipram, Fig. 1), highly associated with cognitive functions [58]. It can improve scopolamine-induced LTM deficits in rats, which is extremely likely triggered by elevated cAMP/PKA signaling [59]. Similarly, in amyloid precursor protein/presenilin-1 (APP/PS1) transgenic mice with cognitive deficits, long-term treatment with 3 shows persistent amelioration in cognitive abilities.

    View all citing articles on Scopus
    View full text